Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities  by HUBER, B et al.
Seizure 2004; 13: 168–175
doi:10.1016/S1059-1311(03)00154-7
Efficacy and tolerability of levetiracetam in patients
with therapy-resistant epilepsy and learning
disabilities
B. HUBER, W. BÖMMEL, I. HAUSER, V. HORSTMANN, S. LIEM, TH. MAY, T. MEINERT, E.
ROBERTSON, L. SCHULZ, M. SEIDEL, M. TOMKA-HOFFMEISTER & W. WAGNER
Bethel Epilepsy Centre, Ebenezerweg 12, 33617 Bielefeld, Germany
Correspondence to: Dr Bernd Huber, Bethel Epilepsy Centre, Ebenezerweg 12, 33617 Bielefeld, Germany.
E-mail: Aerztlicher-Dienst@t-online.de
Introduction: The purpose was to evaluate the effects of levetiracetam (LEV) in routine therapy in learning disabled patients
with therapy-resistant epilepsy.
Methods: In an open observational add-on study design, 46 patients (residents of the Bethel Epilepsy Centre) with severe
therapy-resistant epilepsy and different degrees of learning disabilities, who were treated with LEV between its introduction in
Autumn 2000 and February 2002, were evaluated retrospectively. Information on monthly seizure frequencies, seizure severity
and psychiatric status was extracted from the current patient case records. A 3 months baseline and a 3 months LEV treatment
period (after 3 months of titration) were compared. Responders were defined as having a 50% reduction in seizure frequency
and being evaluated as good or very good in an ad hoc global clinical efficacy scale. When only one criterion was positive, a
careful individual decision was made based on the impact on the patients’ daily activities.
Results: The responder rate was 41.3% (34.8 for 50% seizure reduction). It was higher in focal and multifocal epilepsy as
compared to symptomatic generalised epilepsy/Lennox Gastaut Syndrome (P < 0.05). Antiepileptic response occurred in doses
between 500 and 4000 mg/day. Changes in seizure severity were rare. Nine patients experienced positive psychotropic effects
(mostly improved vigilance and mood); six of these patients had antiepileptic effects as well. Twelve patients had adverse effects,
mostly mild; in three cases, however, more severe effects led to discontinuation.
Conclusions: LEV is an effective and generally well-tolerated drug for this patient group, especially in focal and multifocal
epilepsy.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Approximately 20–25% of all people with learning
disabilities suffer from epilepsy, a percentage much
higher than in the general population. A high seizure
frequency, multiple seizure types, frequent complica-
tions, such as status epilepticus or injuries, and a high
rate of therapy resistance characterise many of the
epilepsies in this population. Therefore, the develop-
ment of each new antiepileptic drug (AED) is a glim-
mer of hope for these patients.
On the other hand, knowledge about efficacy and
tolerability of the new AED in this patient group is
limited. Learning disabled patients are often excluded
from the regulatory double-blind placebo-controlled
trials because of difficulties with consent. The assump-
tion of efficacy of the new AED in this patient group,
strictly speaking, is based on the extrapolation of the
data of non-disabled patients. Post-marketing studies
are needed to evaluate the effects of new drugs in these
special populations. There is some literature on the
use of lamotrigine (LTG) in learning disabled patients,
but only a few articles report on gabapentin (GBP),
topiramate (TPM) and the remaining new AEDs.
Levetiracetam (LEV), one of the most recently intro-
duced AED, has been shown to be effective as add-on
therapy in treatment-resistant patients with focal (par-
tial) epilepsies. Efficacy proved to be dose-related with
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daily doses between 1000 and 3000 mg1–3, with no ad-
ditional effect when doses were further increased up
to 4000 mg/day4, 5. Only recently, a report on the use
of LEV in six developmentally disabled patients was
published. This indicated both a good antiepileptic ef-
fect and favourable changes in problem behaviours in
some of these patients6.
The purpose of our study was to examine the efficacy
and tolerability of LEV in therapy-resistant epilep-
tic patients with learning disabilities of varying de-
grees and not excluding those with additional physical
handicaps. The ethical and legal restrictions existing
in patients, most of whom are not able to give their
informed consent, had to be taken into account.
PATIENTS AND METHODS
Inclusion criteria
The Residential Department of the Bethel Epilepsy
Centre provides care for approximately 1200 patients
with difficult-to-manage therapy-resistant epilepsies,
in many cases with accompanying intellectual and/or
neurological deficits. Eligibility criteria included:
Learning disabled adult and adolescent patients with
a confirmed diagnosis of epilepsy, resistant against
at least one traditional AED, but in fact the vast ma-
jority of all study participants were resistant against
several traditional AEDs up to maximum tolerable
dosages and in several cases against one or two new
AEDs (mostly LTG). The staff physicians of the
Bethel Medical Service (mostly neurologists and psy-
chiatrists, all with special experience in the diagnosis
and treatment of epilepsy) selected the patients on
clinical grounds, preferably patients with frequent
and/or disabling seizures. All patients or their legal
representatives had given consent to LEV treatment.
Forty-eight patients were started on LEV between its
introduction in Germany in Autumn 2000 and Febru-
ary 2002. Two patients had to be excluded from the
study because seizure documentation was incomplete
or unreliable in these cases and so, 46 patients were
enrolled in the study.
Methods
The baseline period was defined as the 3 months prior
to starting LEV treatment. The first 3 months on LEV
were considered to be the titration period, the second 3
(4th–6th) months as treatment or evaluation period. A
post-evaluation after 1 year comprises the 10th–12th
months on LEV. A second post-evaluation after 2 years
is planned, but is not subject of this paper because
data are still incomplete.
LEV was added to the pre-existing medication pre-
scribed for each patient. There was no fixed titration
scheme. Usually, LEV treatment was started follow-
ing the manufacturer’s recommendations (initial dose
1000 mg/day, divided in two doses), but some physi-
cians preferred to start at lower dosages. Progressive
dosage increases followed subject to clinical obser-
vations. A maximum dosage of LEV was not pre-set;
the aim was to obtain the best possible antiepileptic
effects. Clinicians were allowed to adjust the dose of
the concomitant AED if it was considered clinically
appropriate.
The method of this study is in accordance with
the guidelines for observational studies published in
Reference 7. According to these guidelines, an obser-
vational study is a form of a phase IV post-marketing
study which aims to evaluate the benefits and risks of
a drug under natural conditions. Therefore, the study
should not interfere with routine therapy. For that
reason, consent to the new treatment by the patient
or his/her legal representative is needed, but not to
study participation. The different points of time and
the size of data to be raised have to be exactly deter-
mined a priori in order to obtain valid data despite
the shortcomings of an open study7.
The methods and time frames of this study were
very similar to other studies on new AED conducted
previously in our institution8–10; it was intended
to compare the results to those of the previous
studies.
Documentation
Data were extracted retrospectively from the contin-
ual seizure records kept on all resident patients and
entered into data sheets designed for the purpose of
this study. As the institution is specialising in epilepsy
and most staff are trained in observing and describing
seizures, it is believed that the seizure documentation
is as complete and accurate as possible. Besides di-
agnostic data, medication and seizure frequency per
seizure type, possible qualitative changes in seizure
severity were noted. Information on seizure severity
is based upon staff observations and the patients’ own
experiences, as summarised by the responsible physi-
cian. Criteria applied to judge seizure severity were:
seizure duration, time and depth of unconsciousness,
and time to complete recovery.
Possible psychotropic effects, as judged clinically
by the physicians, and adverse effects (defined as
any undesirable effects or patients’ complaints when
considered probably due to LEV) were recorded,
too.
The phenomenological seizure classification cur-
rently in use in Bethel is similar to the proposal for
170 B. Huber et al.
a revision of the classification of the International
League Against Epilepsy11.
Evaluation
As the usual criterion of a 50% seizure reduction
is quite arbitrary, an additional evaluation of global
clinical efficacy (a 5-point ad hoc-scale: very good,
good, modest, none or deteriorated) was made by
the physicians. Global clinical efficacy comprises not
only numerical effects but also aspects of seizure
severity or efficacy against different seizure types.
In the same way, overall tolerability was clinically
judged (very good, good, moderate, bad) by the
treating physicians, based upon staff information and
direct patient examination.
A patient was considered a responder, when he or
she had at least a >50% seizure reduction and global
clinical efficacy was judged very good or good and
the patient was still on LEV at the time of evaluation.
When clinical efficacy was judged very good or good
without a 50% seizure reduction, or when a 50%
seizure reduction was present but clinical efficacy
was judged less than good (when the two criteria
diverged), the responsible physician was contacted
by the first author and the case judged individually
according to the considered relevance of the LEV
effects for the patient’s daily activities (details see
RESULTS, Table 6). Thus, the combination of the
two efficacy measures was thought to reflect LEV
efficacy as realistic as possible.
RESULTS
The 46 patients’ (23 female, 23 male) mean age was
37.0 (range: 13–70) years, their mean duration of
Table 1: Epileptic syndromes and seizure types.
Epileptic syndrome Seizure type
Tonic Psychomotor GTCS Series, status Falls Myoclonic Auras Absence
Symptomatic/cryptogenic focal/partial
epilepsy (n = 20)
7 8 5 4 5 1 5 1a
Epilepsy with both generalised and focal
seizures (n = 8)
3 4 3 2 1 2
Lennox Gastaut Syndrome (n = 7) 5b 4 2 3 1 2 1 3
Symptomatic/cryptogenic multifocal
epilepsy (n = 7)
4 2 5 3 2 1 1
Symptomatic/cryptogenic generalised
epilepsy (n = 3)
2 1 1 1
Progressive myoclonus epilepsy (n = 1) 1 1 1
GTCS: generalised tonic–clonic seizure.
a In the phenomenological seizure classification, any absence-like seizure will be classified as an absence seizure.
b Any seizure type was only evaluated when the minimum frequency of that particular seizure type was 2 per month.
epilepsy 30.5 (range: 8–62) years, and their mean
duration of residential care in Bethel 17.1 (range:
0.5–52) years.
Diagnoses
See Table 1 for diagnoses of epileptic syndromes.
Thirteen patients had mild, 12 had moderate, 11 had
severe/profound learning disability. Ten patients had
borderline intelligence or neuropsychological deficits
like psychomotor slowing or memory disturbance.
Twenty-eight patients had physical handicaps: 5
hemiparesis, 4 tetraparesis, 12 cerebellar syndrome
(in 5 cases combined with different forms of paresis),
1 extrapyramidal syndrome, 1 aphasia. In other cases,
the exact nature of neurologic impairment was not
determined. Eighteen patients were neurologically
normal.
Twenty-three patients had a history of psychiatric ill-
ness, diagnosed by a staff physician familiar with psy-
chiatric disorders in the learning disabled or, in some
cases, by a psychiatrist. The most frequent psychiatric
diagnoses were affective disorder (5), psychosis (4),
behavioural disorder (4), dementia (4) and personality
disorder (3).
Antiepileptic medication
There were only minor changes in concomitant anti-
epileptic medication (see Table 2) between baseline
and treatment period: phenobarbitone (PB), oxcar-
bazepine (OCBZ), topiramate (TPM), carbamazepine
(CBZ), methsuximide (MSM), gabapentin (GBP) and
sulthiame (ST) were discontinued in one case each.
The mean daily dose or serum concentration of val-
proate (VPA), OCBZ and TPM was somewhat lower
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Table 2: Antiepileptic medication during baseline and treatment period.
AED Baseline (n) Treatment (n) Daily dose Serum concentration
Baseline (x ± SD) Treatment (x ± SD) Baseline (x ± SD) Treatment (x ± SD)
LEV 46 2423.9 ± 1177.2 26.9 ± 29.1
VPA 33 33 2136.4 ± 1210.1 1854.5 ± 1092.3 83.2 ± 30.5 73.4 ± 28.1
LTG 19 19 358.4 ± 198.6 360.5 ± 185.5 13.3 ± 4.1 13.8 ± 3.2
PB 14 13 131.8 ± 42.1 129.6 ± 50.6 29.0 ± 8.7 28.1 ± 9.0
OCBZ 9 8 1833.3 ± 698.7 1425.0 ± 680.3 20.3 ± 7.9 16.2 ± 7.6
TPM 6 5 375.0 ± 247.0 265.0 ± 306.5 8.3 ± 3.1 6.0 ± 3.0
PHT 5 5 350.0 ± 39.5 347.4 ± 37.9 19.2 ± 8.1 21.6 ± 10.0
CBZ 5 4 1360.0 ± 185.1 1262.5 ± 213.6 7.6 ± 1.0 7.9 ± 0.9
MSM 4 3 675.0 ± 567.9 700.0 ± 458.3 29.1 ± 12.5 23.9 ± 12.2
x: mean; SD: standard deviation.
LEV: levetiracetam; VPA: valproate; LTG: lamotrigine; PB: phenobarbitone; OCBZ: oxcarbazepine; TPM: topiramate; PHT: phenytoin;
CBZ: carbamazepine; MSM: methsuximide.
Table 3: Efficacy measure 1: reduction in seizure frequency.
Reduction seizure frequency n %
Seizure free 2 4.3
90% reduction 3 6.5
50% reduction 11 23.9
No change 28 60.9
50% deterioration 2 4.3
during treatment compared with baseline period. No
other AED besides LEV was started.
Effects on seizure frequency
After 6 months, 39/46 (85%) patients were still on
LEV. In 7/46 (15%) patients, LEV was discontinued,
in all cases because of a lack of efficacy, and additional
problems with side effects in 1.
2/46 (4%) patients became completely seizure free,
3/46 (6%) patients experienced a 90% seizure reduc-
tion, and another 11/46 (24%) patients a 50% seizure
reduction (Table 3; efficacy measure 1). In 20/46
(43.5%) patients, global clinical efficacy was judged
good or very good by the treating physicians (Table 4;
efficacy measure 2).
In 12/46 (26%) patients, the two efficacy measures
were concurrently positive, they were responders
(Table 5). 22/46 (48%) patients were non-responders
following both measures. In 12/46 patients, the two
Table 4: Efficacy measure 2: global clinical efficacy.
Global clinical efficacy n %
Very good 6 13.0
Good 14 30.4
Modest 13 28.3
No effect 11 23.9
Deterioration 2 4.3
Table 5: Synopsis: efficacy measures.
50% reduction of Global clinical N Responder Non-
seizure frequency efficacy responder
+ + 12 12
+ − 4 7
− + 8 5
− − 20 20 (+2a)
a Including two cases of deterioration.
efficacy measures disagreed. As mentioned above,
these cases were discussed with the responsible physi-
cians and judged individually, with the emphasis on
the impact the new treatment had had on the patients’
daily lives. From this group of 12, 7 were considered
responders, 5 were considered non-responders. For
the individual reasons see Table 6.
Overall, therefore, the number of responders is 19
out of 46 patients, corresponding to a responder rate
of 41.3%.
Efficacy in different seizure types and
epileptic syndromes
Improvement rates differ considerably between the
different seizure types (Fig. 1). Greatest benefits
were seen in patients with isolated auras, my-
oclonic seizures and generalised tonic–clonic seizures
(57.1, 42.9 and 41.2%, respectively) and lowest in
tonic seizures and absence seizures (21.1 and 0%,
respectively).
The number of responders in the different epilep-
tic syndromes is shown in Fig. 2. Responder
rates in focal/multifocal epilepsy were better than
those in generalised epilepsy (Lennox Gastaut
Syndrome and symptomatic or cryptogenic gen-
eralised epilepsy, taken together), the difference
reaching significance (P = 0.028, Fisher’s exact
test).
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Table 6: Individual judgement (responder or non-responder) and the respective reasons when efficacy measures disagreed.
Patient (gender) Age (years) % seizure reduction Clinical efficacy Responder Reasons
SH (m) 23.6 50 Modest Yes Improvement in seizure severity too; seizure
reduction relevant for daily activities
JS (w) 23.9 90 No effect No Temporary ‘improvement’ considered as
spontaneous course, not as LEV effect; LEV
discontinued
DN (m) 37.8 50 No effect No Extremely high baseline seizure frequency,
50% reduction not relevant for daily activities
PA (m) 52.8 50 Modest No Exactly 50% reduction, not relevant for daily
activities
MS (w) 34.1 No change Good Yes Discontinuation of badly tolerated
co-medication made possible by add-on LEV
KK (m) 25 No change Good Yes Additional ‘if required medication’ less
frequently needed; better general state
AG (w) 37.2 No change Good Yes On LEV seizures nearly exclusively during
sleep; no more falls
UC (m) 41.4 No change Good Yes Falls considerably less frequently, less
injuries, less emergencies (hospital)
CK (w) 41.9 No change Good No Improved general state due to positive
psychotropic effects, not to antiepileptic effect
MG (m) 21.7 No change Good Yes Less series, less falls
CS (w) 16.2 No change Good No Discontinued
JM (m) 70.5 No change Good Yes During baseline four emergencies to hospital,
during treatment period none
Efficacy in relation to LEV dosage and serum
concentration and to co-medication
The mean daily LEV dosage is slightly lower in re-
sponders than in non-responders, whereas the mean
serum concentrations are very similar (Table 7).
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Fig. 1: Seizure reduction in the different seizure types.
*Responder rate: percentage of patients with at least 50%
reduction of that seizure type.
Responders also have slightly higher mean dosages
and serum concentrations of PB, LTG and OCBZ, but
as the values (given in brackets in Table 7) indicate,
there is no major difference in these co-medications
between the baseline and treatment period.
Eight responders, but only five non-responders, have
PB as co-medication (P = 0.104, Fisher’s exact test).
All in all, the differences in medication between
responders and non-responders were minor.
Qualitative changes in seizure severity
Three patients had milder or shorter seizures, in one
of these cases post-ictal recovery was shorter. In an-
other patient, seizures in the treatment period occurred
nearly only at night during sleep. In four patients, the
propensity to seizure clusters and to seizure-related
falls was diminished, but these changes were counted
as quantitative improvements (Fig. 1).
Psychotropic effects
In 10/46 (22%) patients, psychotropic effects were re-
ported, positive changes in 9 cases, unwanted effects
in 1 case. There were no psychotropic effects in the
remaining patients.
The positive psychotropic effects were mainly an
improvement in vigilance, more activity, improved
mood, and in two cases more stable mood.
The nine patients with positive psychotropic ef-
fects had LEV dosages between 1000 and 4000 mg/
day (mean 2778 mg/day) and serum concentrations
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Fig. 2: Responder rates in the different epileptic syndromes.
between 9 and 67.1µg/ml (mean 28.8µg/ml). Six of
them were responders, three non-responders.
Tolerability/adverse effects
(including unwanted psychotropic effects)
Tolerability, as clinically judged by the treating physi-
cians, was very good (23 cases) or good (13 cases)
in most patients. In seven patients, tolerability was
moderate, in two cases poor (one case: not evaluable).
Twelve patients or their carers reported adverse ef-
fects. Somnolence was the most frequent adverse ef-
fect (5 cases), followed by mild ataxia (2), vomiting
(1) and loss of appetite (1).
In only three cases were adverse effects severe: One
patient with a pre-existing cerebellar syndrome de-
teriorated to the point, she was no longer able to
Table 7: Antiepileptic medication in responders versus non-responders.
AED Responder Non- Daily dose (mg/day) Serum concentration (µg/ml)
(n) responder
Responder Non-responder Responder Non-responder
x Minimum– x Minimum– x Minimum– x Minimum–
maximum maximum maximum maximum
LEV 19 27 2210.5 500–4000 2574.1 500–4000 22.4 9–53.5 21.1 3.5–67.1
VPA 12 21 1975.0 300–4800 1785.7 450–4000 68.7 30.4–97.1 75.0 21.8–156.9
PB 8∗ 5∗ 134.4a (131.8) 50–200 122.0 50–150 31.7a (29.0) 18.4–43.7 23.9 13.5–34.1
LTG 6 13 433.3a (358.4) 275–700 326.9 100–800 15.7a (13.3) 12.7–20.1 13.3 6.2–18.4
OCBZ 4 4 1837.5a (1833) 1500–2400 1012.5 150–1800 17.4a (20.3) 13.9–19.7 15.1 0.5–26.6
a As these values differ slightly between responders and non-responders, the values before LEV treatment are given in brackets for
comparison.
∗ P = 0.104.
walk without support (1500 mg/day LEV; 3.5µg/ml;
dosage and serum concentration of concomitant CBZ
were unchanged).
The second patient suffered from unwanted psy-
chotropic effects (apathy, somnolence, impaired con-
sciousness, and a reduction in drive and activity) on
1000 mg/day LEV (3.9µg/ml).
Only during the post-evaluation phase did a third pa-
tient develop a paranoid-hallucinatory psychosis when
LEV dosage was increased from 1000 to 2000 mg/day
(serum concentration not determined). This patient
had a pre-existing personality disorder but no known
history of psychosis. Despite discontinuation of LEV,
psychotic symptoms were only incompletely resolved.
An additional case involved an increase in aggres-
sion. But this case could possibly be attributed to a
reduction of concomitant LTG which had formerly
improved aggressive behaviours in this patient.
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One patient had tremor, dizziness and gait distur-
bance (3000 mg/day LEV; 32.4µg/ml), but this could
have been secondary to withdrawal of concomitant
primidone.
Post-evaluation after 12 months
After 1 year of LEV treatment, 22/46 (48%) patients
were still on LEV, in 17 patients LEV was discontin-
ued (in 7 patients, the duration of LEV treatment was
less than 12 months).
Whilst re-evaluating the data at 1 year, two of the
former responders had experienced an increase in
seizure frequency and no longer fulfilled the criteria
for responders, but two of the former non-responders
had improved and thus could be considered to be
responders.
DISCUSSION
Although the efficacy of LEV is sufficiently proven
in general patient populations, there are limited data
regarding its use in learning disabled patients. This
retrospective observational study was undertaken to
assess LEV effects in therapy-resistant resident pa-
tients of the Bethel Epilepsy Centre.
The responder rate of 41.3% seems very good in
what is a difficult-to-treat patient group. The respon-
der rate is best in the focal epilepsy syndromes, the
accepted main indication for LEV, whereas in the
generalised epilepsy syndromes efficacy proved to be
only 10%, although the number of 10 patients with
Lennox Gastaut Syndrome or other symptomatic gen-
eralised epilepsy is relatively small. Within seizure
syndromes, efficacy was found to be high in focal
seizure types (auras, psychomotor seizures), but low
in seizure types, such as absence seizures, which are
mostly generalised (see footnotes to Table 1). As for
generalised tonic–clonic and tonic seizures, it is diffi-
cult to determine in a retrospective study whether they
are focal/focal-onset or primarily generalised. How-
ever, further analysis shows 5 out of 10 (50%) patients
with generalised tonic–clonic seizures within a focal
or multifocal epilepsy, and 5 out of 11 (45.5%) pa-
tients with tonic seizures within a focal or multifocal
epilepsy had at least a 50% reduction of that particular
seizure type. Thus, generalised tonic–clonic seizures
as well as tonic seizures in patients with focal epilepsy
syndromes respond very well to LEV. Simple focal
(partial) seizures other than auras were too rare to be
evaluated.
The one patient with a progressive myoclonus epil-
epsy responded excellently.
To further evaluate treatment outcomes, we used
the usual 50% seizure reduction criterion but also in-
cluded a more individualised global clinical efficacy
measure. It could be argued that this gives only a sub-
jective opinion, however, all cases in question have
been carefully evaluated and the reasons for decisions
are transparent (Table 6). Therefore, we feel this is a
more adequate way of judging efficacy than only ad-
hering to seizure numbers and reflects clinical practice
where decisions are made on more than just seizure
reduction. If one prefers to keep to the formal 50%
seizure reduction measure, a slightly lower responder
rate (16/46 patients or 34.8%) would result (Table 3).
LEV dosages and serum concentrations were quite
similar in responders and non-responders. It was our
experience that individual patients could respond to
any LEV dose within the usual dosage spectrum of
500–4000 mg/day (serum concentrations between 9
and 53.5µg/ml). We found no convincing indication
for certain co-medications to be more favourable than
others.
Qualitative changes in seizure severity occurred only
in a small minority of patients.
Nearly one fifth of patients had positive psy-
chotropic effects. Six of these patients also had better
seizure control, three did not. It remains difficult to
evaluate whether these psychotropic effects are an
independent drug effect or secondary to improved
seizure control.
Unwanted psychotropic effects occurred very rarely.
The one patient who developed a first episode of psy-
chosis on a rapid LEV dosage increase is notable,
however, the psychosis did not fully resolve following
discontinuation.
Drug tolerability, which in general can be decreased
in neurologically impaired patients, proved to be good
to very good in the great majority of patients. Most
side effects were mild and remitted spontaneously or
when the dose was reduced. Strikingly, two of three
patients who experienced more severe side effects
did so with low LEV doses and serum concentra-
tions. The most frequent side effect was somnolence
which occurred with LEV dosages between 2500 and
4000 mg/day. In some cases, somnolence was noticed
when LEV dosage was rapidly increased, e.g. by
500 mg b.i.d. In these cases, dosage increments were
reduced to 250 mg b.i.d. or 250 once a day.
We have earlier reported on similar studies with
LTG, TPM and GBP in the same patient population. In
those studies, we found similarly high responder rates
of 28.8% for LTG8 and 37.5% for TPM10, but only
10.3% for GBP9. Tolerability was also good in LTG
and GBP, whereas a considerable number of serious
side effects occurred with TPM. With LTG, positive
psychotropic effects occurred even more frequently
than those observed in LEV, and were apparently
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independent from the antiepileptic effect. LTG, which
at the time was only approved for focal epilepsy (like
LEV is at present), proved to be equally effective in
generalised epilepsy.
We are aware of the well-known shortcomings of
poorly controlled retrospective studies. Nevertheless,
we feel the presented data are valid. Major bias by the
responsible physicians or staff is improbable because
all seizure documentations were part of the regular
documentation which is kept on all resident patients
independently. Moreover, we attempted to minimise
effects of spontaneous fluctuations in seizure fre-
quency by calculating frequency as mean values of
3 months.
CONCLUSIONS
In our experience, LEV is an effective and gener-
ally well-tolerated therapy in the difficult-to-treat
epilepsies of learning disabled patients. This is es-
pecially true for focal epilepsies/focal seizure types.
The efficacy in symptomatic/cryptogenic generalised
epilepsy remains to be determined; in our study it was
minor.
LEV can have positive psychotropic effects like im-
proved vigilance and better or more stable mood in a
number of patients. Further study is needed to clarify
if this a genuine drug effect or rather a consequence
of better seizure control.
As the desired antiepileptic effect can occur at very
different doses, it is advisable to titrate stepwise and
watch effects. The titration scheme recommended by
the manufacturer (steps of 500 mg b.i.d.) may be too
rapid for disabled patients, temporary side effects,
such as somnolence, may happen less frequently when
a slower titration scheme is applied.
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